<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656461</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-106</org_study_id>
    <nct_id>NCT00656461</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of MKC-1 in Patients With Advanced Cancer</brief_title>
  <official_title>Phase 1 Study of MKC-1 in Patients With Advanced or Metastatic Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CASI Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CASI Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study to determine the highest dose of MKC-1 that may be administered&#xD;
      daily on a continuous basis for patients with advanced or refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) of MKC-1 administered orally twice a day (bid) continuously in patients with advanced or refractory solid tumors.</measure>
    <time_frame>Throughout study participation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine evidence of benefit in cancer patients when MKC-1 is administered orally twice a day (bid) continuously by evaluating tumor response and/or tumor marker improvement.</measure>
    <time_frame>During study participation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MKC-1</intervention_name>
    <description>30 mg and 100 mg capsules, dosed BID daily on a continuous schedule</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histologically confirmed malignancy that is metastatic or unresectable and for&#xD;
             which standard curative measures do not exist or are no longer effective.&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  ECOG performance status ≤1&#xD;
&#xD;
          -  ANC greater than or equal to 1,500/mm3;&#xD;
&#xD;
          -  Platelets greater than or equal to 100,000/mm3&#xD;
&#xD;
          -  creatinine ≤1.5 times institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  T Bili within normal limits;&#xD;
&#xD;
          -  AST and ALT less than or equal to 2.5 times ULN; and&#xD;
&#xD;
          -  albumin greater than or equal to 3.0 g/dL&#xD;
&#xD;
          -  have measurable disease by RECIST, radiographically evaluable disease, or detectable&#xD;
             disease&#xD;
&#xD;
          -  women of child-bearing potential and men must agree to use adequate contraception&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have previously received MKC-1.&#xD;
&#xD;
          -  Have received radiation to greater than 25% of the bone marrow.&#xD;
&#xD;
          -  Have had anti-cancer therapy within 4 weeks prior to entering the study or those who&#xD;
             have not recovered from adverse events due to agents administered more than 4 weeks&#xD;
             earlier.&#xD;
&#xD;
          -  Are concurrently receiving any other investigational agents while on study.&#xD;
&#xD;
          -  Have known brain metastases&#xD;
&#xD;
          -  Have any condition that impairs the ability to swallow and retain MKC-1 capsules.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Are pregnant or breastfeeding&#xD;
&#xD;
          -  HIV-positive patients&#xD;
&#xD;
          -  Patients with uncontrolled diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U. of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U. of Wisconsin Paul P. Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>April 7, 2008</study_first_submitted>
  <study_first_submitted_qc>April 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2008</study_first_posted>
  <last_update_submitted>November 23, 2009</last_update_submitted>
  <last_update_submitted_qc>November 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Miikana Therapeutics, an EntreMed, Inc. company</organization>
  </responsible_party>
  <keyword>Advanced cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

